It appears so, but it's hard to believe that a row boat (GNVC) can affect a battleship (XON) that has a market cap around 150 times greater!
<< To some degree I believe this buyout is creating weakness in XON's share price as investors can purchase GNVC at barely over .297 of XON and know they may see $1 or more a share if the hearing drug moves forward in the next 3 years. >>
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.